Evidence map›Paper›PMID 24182700›Full record

ArticleMayo Clinic proceedings2013

Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.

Vincenzo De Giorgi, Sara Gandini, Marta Grazzini, Silvia Benemei, Niccolò Marchionni, Pierangelo Geppetti

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01988831 phase2suspendednot on this mapstarted 2016, after this paper: background citation

Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial

TypeinterventionalSponsorUniversity Hospital, GenevaRan2016 to 2022Enrolled450ConditionsStages III Skin Melanoma, Stages II Skin Melanoma, Stage IB Skin MelanomaArmsPropranolol hydrochloride, Placebo pill
NCT02962947 phase2 / phase3unknown statusnot on this mapstarted 2017, after this paper: background citation

Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence

TypeinterventionalSponsorAzienda Sanitaria di FirenzeRan2017 to 2022Enrolled546ConditionsMelanomaArmsPropranolol, Placebo
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Targeting the βThe Journal of pathology · 2023
    Article
  7. Article
  8. Review
  9. Dissecting the role of cell signaling versus CD8Journal of molecular medicine (Berlin, Germany) · 2022
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. The Role of β-Blockers in Melanoma.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vincenzo De GiorgiDepartment of Dermatology, University of Florence, Florence, Italy. Electronic address: vincenzo.degiorgi@unifi.it.
Sara Gandini
Marta Grazzini
Silvia Benemei
Niccolò Marchionni
Pierangelo Geppetti
University of Florence · ITEuropean Institute of Oncology · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo verify preliminary studies on patients with melanoma exposed to β-blockers that suggested a reduced risk of disease recurrence and death. PATIENTS AND

methodsData were obtained from all consecutive patients diagnosed as having melanoma between January 1, 1993, and December 31, 2009, at the Department of Dermatology of the University of Florence, Azienda Sanitaria di Firenze. Participants were excluded if at baseline they reported a previous diagnosis of cutaneous malignant melanoma or another malignant disease. We also excluded participants with evidence of visceral, lymph nodal, and in-transit metastasis at the time of the diagnosis.

resultsOf 741 consecutive patients with melanoma, 79 (11%) were prescribed β-blockers (for hypertension in most cases) for 1 or more years (treated) and 662 (89%) were not (untreated). The multivariate Cox model indicated that the treated group had improved overall survival after a median follow-up of 4 years (P=.005). For each year of β-blocker use, the risk of death was reduced by 38%. The presence of hypertension, the use of antihypertensive agents for 1 or more years, or the use of other commonly used medicines were not associated with a better outcome for patients with melanoma.

conclusionThe results confirm and strengthen previous findings that β-blocker use is associated with a reduced risk of melanoma recurrence and death. The results also indicate the strong need for a randomized clinical trial to conclusively assess whether β-blockers afford protection against melanoma recurrence and death.

Indexed as

Adrenergic beta-AntagonistsAdultAntihypertensive AgentsCutaneous Malignant MelanomaFemaleFollow-Up StudiesHumansHypertensionItalyMaleMelanomaMiddle AgedNeoplasm Recurrence, LocalRisk FactorsSkin NeoplasmsSurvival AnalysisAdrenergic beta-AntagonistsAntihypertensive AgentsACEIangiotensin-converting enzyme inhibitorangiotensin receptor blockerARBCMMcutaneous malignant melanomaDFSdisease-free survivalhazard ratioHROSoverall survival

Identifiers

PMID24182700
OpenAlexW2087352349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.